Videourodynamic Studies of Women with Voiding Dysfunction

Sheng-Mou Hsiao¹,²,³, Ho-Hsiung Lin¹,³ & Hann-Chorng Kuo⁴

This retrospective study is aimed to present videourodynamic findings of women with symptoms of voiding dysfunction in a medical center. Of 1914 women, the diagnoses included bladder outlet obstruction (BOO, \( n = 810, 42.3\% \)), bladder dysfunction (\( n = 1,048, 54.8\% \)) and normal tracings (\( n = 56, 2.9\% \)). Anatomic BOO (\( n = 49 \)) included cystocele (\( n = 19 \)) and urethral stricture (\( n = 30 \)). Common functional BOOs included dysfunctional voiding (\( n = 325, 17.0\% \)) and poor relaxation of the external sphincter (\( n = 336, 17.6\% \)). Common bladder dysfunction subtypes included detrusor underactivity (\( n = 337, 17.6\% \)), detrusor hyperactivity with impaired contractility (\( n = 231, 12.1\% \)), and bladder oversensitivity (\( n = 325, 17.0\% \)). Receiver operating characteristic (ROC) analysis were performed, and the following optimum cutoff values were determined: (1) voiding detrusor pressure at a maximum flow rate (Pdet.Qmax) = 30 cmH2O for differentiating BOO from bladder dysfunction and normal tracings, with an ROC area of 0.78; (2) the Abrams-Griffiths number = 30 for differentiating anatomic from functional BOO, with an ROC area of 0.66; (3) post-void residual = 200 mL for differentiating bladder neck dysfunction from the other BOOs, with an ROC area of 0.69; (4) Pdet.Qmax = 30 cmH2O for differentiating dysfunctional voiding from poor relaxation of the external sphincter with an ROC area of 0.93. The above findings can be used as initial guide for management of female BOO.

Clinical lower urinary tract symptoms of women are not reliable for the diagnosis of lower urinary tract dysfunction¹. Symptoms-based treatment may be ineffective and may also expose patients to unnecessary treatment-related adverse effects. Pressure flow urodynamic studies can be used to diagnose bladder outlet obstruction (BOO)³. However, the management of BOO may differ among its subgroups⁵. Videourodyamics can provide a definitive diagnosis for women with voiding symptoms⁴–⁷. Nonetheless, many urodynamic units do not have fluoroscopy, and fluoroscopy would result in a small but significant radiation exposure for the patients, technicians or even physicians.

Thus, it is preferred to make a differential diagnosis in women with voiding symptoms using test without radiation, such as uroflowmetry or urodynamic studies, thereby avoiding radiation exposure. Therefore, the main aim of this study is to determine if any parameters of urodynamic studies can be used as initial guide for the differential diagnosis of women with voiding dysfunction. In addition, the main cause of female BOO is controversial⁷,⁸, we also aim to present the videourodynamic findings in women with symptoms of voiding dysfunction.

Results

Of 1914 women, the diagnoses included bladder outlet obstruction (BOO, \( n = 810, 42.3\% \)), bladder dysfunction (\( n = 1,048, 54.8\% \)) and normal tracings (\( n = 56, 2.9\% \)) (Table 1). BOO included functional and anatomic BOOs. Anatomic BOO included urethral stricture (\( n = 30 \), Fig. 1A) and cystocele (\( n = 19 \)). Functional BOOs included bladder neck dysfunction (\( n = 100, 5.2\% \), Fig. 1B), dysfunctional voiding (\( n = 325, 17.0\% \), Fig. 1C) and poor relaxation of the external sphincter (\( n = 336, 17.6\% \), Fig. 1D) (Table 2). The most common types of bladder dysfunction were detrusor underactivity (\( n = 337, 17.6\% \)), bladder oversensitivity (\( n = 325, 17.0\% \)) and detrusor hyperactivity and impaired contractility (\( n = 231, 12.1\% \)).

Receiver operating characteristic (ROC) analyses were performed, and the following optimum cutoff values were determined: (1) voiding detrusor pressure at maximum flow rate (Pdet.Qmax) = 30 cmH2O for differentiating BOO from bladder dysfunction and normal tracings, with a ROC area of 0.78 (95% confidence interval [CI] = 0.76 to 0.80; sensitivity = 54.6%, specificity = 91.8%) (Fig. 2A); (2) the Abrams-Griffiths number (i.e.,

¹Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, Banqiao, New Taipei, Taiwan. ²Graduate School of Biotechnology and Bioengineering, Yuan Ze University, Taoyuan, Taiwan. ³Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan. ⁴Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan. Correspondence and requests for materials should be addressed to H.-C.K. (email: hck@tzuchi.com.tw)
The cutoff values for uroflowmetry and urodynamic parameters for female BOO are controversial. The criterion of Qmax to define female BOO ranges from 11 mL/s to 15 mL/s, and the Pdet.Qmax ranges from 60 (sensitivity 74.1%, specificity 83.0%) to 80 cmH2O (sensitivity 76.5%, specificity 74.1%) (Fig. 2B), and Pdet.Qmax = 30 cmH2O was the best cutoff for differentiating dysfunctional voiding from poor relaxation of the external sphincter, with a ROC area of 0.93 (95% CI = 0.91 to 0.95; sensitivity = 87.7%, specificity = 83.0%) (Fig. 2D).

If we used the bladder contractility index (i.e., Pdet.Qmax + 5 × Qmax) to predict bladder dysfunction in all women with symptoms of voiding dysfunction, the ROC area was 0.70 (95% CI = 0.68 to 0.73) with a cutoff point of 60 (sensitivity = 70.9%, specificity = 59.7%) (Fig. 2E).

The incidences of moderate/severe voiding symptoms did not differ between the BOO and bladder dysfunction groups (62% and 60%, respectively, P = 0.31, Table 1). Nonetheless, higher incidences of urgency/urgency urinary incontinence and frequency/nocturia, and lower incidence of urinary retention were noted in the BOO group, compared with the bladder dysfunction group (Table 1).

Table 1. Comparisons of videourodynamic diagnoses in women with voiding dysfunction symptoms (n = 1,914). Data were expressed as the mean ± standard deviation or number (percentage). BOO = bladder outlet obstruction; Pdet.Qmax = voiding detrusor pressure at Qmax; Qmax = maximum flow rate; and UUI = urgency urinary incontinence. *By Kruskal-Wallis test or chi-square test. 1By Wilcoxon rank-sum test or chi-square test.

| Variables                        | BOO (n = 810)       | Bladder dysfunction (n = 1,048) | Normal tracings (n = 56) | P* | BOO vs. Bladder dysfunction, P* |
|----------------------------------|---------------------|---------------------------------|--------------------------|----|---------------------------|
| Age (years)                      | 59.3 ± 16.7         | 64.7 ± 16.2                     | 54.0 ± 14.3              | 0.0001 | <0.0001          |
| Detrusor overactivity            | 282 (35)            | 306 (29)                        | 0 (0)                    | 0.001 | 0.01               |
| First sensation of filling (mL)  | 141 ± 69            | 157 ± 92                        | 167 ± 72                 | 0.003 | 0.02               |
| Full sensation (mL)              | 223 ± 97            | 235 ± 117                       | 290 ± 103                | 0.0001 | 0.26               |
| Bladder compliance (mL/cmH2O)    | 71.7 ± 84.8         | 63.5 ± 78.9                     | 84.8 ± 72.0              | 0.001 | 0.0003          |
| Voided volume (mL)               | 202 ± 142           | 152 ± 120                       | 489 ± 114                | 0.0001 | <0.0001          |
| Post-void residual (mL)          | 126 ± 139           | 176 ± 189                       | 20 ± 29                  | 0.0001 | <0.0001          |
| Bladder capacity (mL)            | 329 ± 150           | 328 ± 154                       | 508 ± 120                | 0.001 | 0.31               |
| Pdet.Qmax (cmH2O)                | 33 ± 23             | 14 ± 11                         | 17 ± 8.2                 | 0.0001 | <0.0001          |
| Qmax (mL/s)                      | 8.9 ± 6.2           | 7.8 ± 6.5                       | 24.1 ± 7.8               | 0.0001 | <0.0001          |
| Abrams-Griffith number           | 15.6 ± 26.3         | −1.6 ± 14.4                     | −31.0 ± 17.5             | 0.001 | <0.0001          |
| Voided volume/bladder capacity (%)| 0.63 ± 0.32         | 0.53 ± 0.37                     | 0.96 ± 0.05              | 0.0001 | <0.0001          |
| Hypertension                     | 161 (20)            | 269 (26)                        | 6 (11)                   | 0.04 | 0.04               |
| Diabetes                         | 162 (20)            | 166 (16)                        | 8 (14)                   | 0.053 | 0.02               |
| Coronary artery disease          | 23 (3)              | 41 (4)                          | 2 (4)                    | 0.45 | 0.21               |
| Chronic kidney disease           | 19 (2)              | 21 (2)                          | 2 (4)                    | 0.68 | 0.62               |
| Chronic obstructive pulmonary disease | 13 (2)             | 9 (1)                           | 0 (0)                    | 0.23 | 0.14               |
| Moderate/severe voiding symptoms | 501 (62)            | 624 (60)                        | 18 (32)                  | <0.001 | 0.31           |
| Urgency/UUI                      | 497 (61)            | 550 (52)                        | 39 (70)                  | <0.001 | <0.0001          |
| Frequency/nocturia               | 733 (90)            | 856 (82)                        | 49 (88)                  | <0.001 | <0.0001          |
| Urinary retention                | 88 (11)             | 233 (22)                        | 3 (5)                    | <0.001 | <0.0001          |

**Discussion**

Voiding problems may be due to increased urethral resistance, impaired detrusor contractility or both. We found that only 42.5% of women with symptoms of voiding dysfunction were proven to have anatomic or functional BOO (Table 1). Besides, the incidences of moderate/severe voiding symptoms did not differ between women with BOO and bladder dysfunction (Table 1). Thus, the differential diagnosis for women with symptoms of voiding dysfunction may not depend on clinical symptoms and pelvic examination alone. Urodynamic or videourodynamic studies may be used for differential diagnosis, especially for women who are refractory to medical treatment.

Previously, Groutz et al. reported that prior anti-incontinence surgery and severe genital prolapse were the most common etiologies of female BOOs. Brucker et al. also reported that anatomic BOO was the main cause of female BOO in their study. However, we found that the most common etiologies for BOO were dysfunctional voiding and poor relaxation of the external sphincter, not anatomic BOO (Table 2). The cutoff values for uroflowmetry and urodynamic parameters for female BOO are controversial. The criterion of Qmax to define female BOO ranges from 11 mL/s to 15 mL/s, and the Pdet.Qmax ranges from 21 cmH2O to 50 cmH2O, and a female BOO nomogram has been reported. Nonetheless, Gravina et al. reported that Qmax and Abrams-Griffiths number were the most useful criteria for the diagnosis of urodynamic obstruction, and Pdet.Qmax was the least. However, we found that a Pdet.Qmax ≥ 30 cmH2O was the best cutoff value to differentiate BOO from a normal tracing and bladder dysfunction, comparable to our previous report.
Figure 1. Videourodynamic findings of the subtypes of bladder outlet obstruction: (A) urethral stricture, (B) bladder neck dysfunction, (C) dysfunctional voiding and (D) poor relaxation of the external sphincter.

| Variables                              | BOO                        | Functional BOO | Functional BOO | Functional BOO | Functional BOO | P<sup>a</sup> | Dysfunctional voiding vs. PRES, P<sup>b</sup> |
|----------------------------------------|----------------------------|----------------|----------------|----------------|----------------|--------------|---------------------------------------------|
|                                       | (n = 761)                  | (n = 49)       | (n = 100)      | (n = 325)      | (n = 336)      |              |                                            |
| Age (years)                           | 59.4 ± 13.8                | 57.8 ± 16.7    | 61.1 ± 16.5    | 56.5 ± 15.9    | 0.0001         | 0.0001       |                                            |
| Detrusor overactivity                 | 260 (34)                   | 22 (45)        | 46 (46)        | 19 (6)         | <0.001         | <0.001       |                                            |
| First sensation of filling (mL)       | 141 ± 54                   | 141 ± 57       | 138 ± 78       | 130 ± 69       | 154 ± 64       | 0.0001       | <0.0001                                     |
| Full sensation (mL)                   | 223 ± 77                   | 214 ± 80       | 209 ± 103      | 197 ± 95       | 253 ± 90       | 0.0001       | <0.0001                                     |
| Bladder compliance (mL/cm<sub>H2O</sub>) | 73 ± 55                    | 59 ± 46        | 61 ± 70        | 63 ± 77        | 85 ± 95        | 0.0001       | <0.0001                                     |
| Voided volume (mL)                    | 205 ± 116                  | 166 ± 120      | 142 ± 143      | 179 ± 125      | 248 ± 143      | 0.0001       | <0.0001                                     |
| Post-void residual (mL)               | 126 ± 109                  | 131 ± 109      | 216 ± 187      | 121 ± 123      | 104 ± 126      | 0.0001       | 0.03                                         |
| Bladder capacity (mL)                 | 331 ± 119                  | 297 ± 109      | 358 ± 176      | 300 ± 145      | 352 ± 143      | 0.0001       | <0.0001                                     |
| Pdet.Qmax (cm<sub>H2O</sub>/L)        | 32 ± 17                    | 49 ± 29        | 39 ± 24        | 46 ± 18        | 17 ± 12        | 0.0001       | <0.0001                                     |
| Qmax (mL/s)                            | 9.0 ± 4.7                  | 7.0 ± 4.6      | 6.0 ± 5.6      | 9.4 ± 6.1      | 9.6 ± 6.2      | 0.0001       | 0.23                                         |
| Abrams-Griffith number                | 14 ± 19                    | 35 ± 30        | 27 ± 26        | 27 ± 23        | 27 ± 15        | 0.0001       | <0.0001                                     |
| Voided volume/bladder capacity (%)    | 0.63 ± 0.28                | 0.54 ± 0.30    | 0.41 ± 0.37    | 0.62 ± 0.31    | 0.71 ± 0.30    | 0.0001       | 0.0002                                     |
| Moderate/severe voiding symptoms      | 463 (61)                   | 38 (78)        | 68 (68)        | 176 (54)       | 219 (65)       | 0.004        | 0.004                                        |
| Urgency/UUI                           | 472 (62)                   | 25 (51)        | 56 (56)        | 235 (72)       | 181 (54)       | <0.001       | <0.001                                       |
| Frequency/nocturia                    | 694 (91)                   | 39 (80)        | 89 (89)        | 292 (90)       | 313 (93)       | 0.23         | 0.16                                         |
| Urinary retention                     | 83 (11)                    | 5 (10)         | 20 (20)        | 39 (12)        | 24 (7)         | 0.001        | 0.03                                         |

Table 2. Comparisons of videourodynamic diagnoses with bladder outlet obstruction (n = 810). PRES = poor relaxation of the external sphincter. Data expression and other abbreviations are the same as in Table 1. *By Wilcoxon rank-sum test or chi-square test. †By Kruskal-Wallis test or chi-square test.
The Abrams-Griffiths number has been used to diagnose men with BOO. Using this nomogram, men can be divided into obstructed, equivocal, and unobstructed according to their Abrams-Griffiths number: Abrams-Griffiths number > 40 = obstructed; Abrams-Griffiths number 20–40 = equivocal; and Abrams-Griffiths number < 20 = unobstructed. Gravina et al. reported the use of the Abrams-Griffiths number in diagnosing women with BOO. In this study, although the Pdet.Qmax rather than the Abrams-Griffiths number was better to differentiate women with BOO and bladder dysfunction (Fig. 2A), and Abrams-Griffiths number was found to

Figure 2. The receiver operating characteristic (ROC) curve of using (A) the voiding detrusor pressure at maximum flow rate (Pdet.Qmax) to predict bladder outlet obstruction, (B) the Abrams-Griffiths number to predict anatomic bladder outlet obstruction, (C) the post-void residual to predict bladder neck dysfunction, (D) the Pdet.Qmax to predict dysfunctional voiding, and (E) the bladder contractility index to predict bladder dysfunction.
be a potential tool for differential diagnosis of anatomic BOO from functional BOO. However, owing to low ROC area of Abrams-Griffiths number to differentiate anatomic BOO from functional BOO, videourodynamic studies should remain an important tool for differential diagnosis. Brucker et al. reported that Qmax is significantly lower in anatomic BOO. We found that the ROC area of the Abrams-Griffiths number (Fig. 2B) did not differ from the ROC area of Qmax in predicting anatomic BOO (0.66, 95% CI = 0.58 to 0.74 vs. 0.62, 95% CI: 0.54 to 0.70, P = 0.43). Owing to low ROC areas of the Abrams-Griffiths number and Qmax, both parameters should not be used as good tools for differential diagnosis of anatomic and functional BOOs.

The treatment of bladder neck dysfunction may differ from the treatment of dysfunctional voiding and poor relaxation of the external sphincter. Bladder neck dysfunction is caused by a lack of relaxation of the smooth muscles at the bladder neck during the voiding phase. Bladder neck dysfunction, dysfunctional voiding and poor relaxation of the external sphincter can be treated with alpha blockers, clean intermittent catheterization or botulinum A injection; however, their specific treatments may differ. Transurethral incision of the bladder neck can provide definitive treatment for bladder neck dysfunction, while the first-line treatment for dysfunctional voiding and poor relaxation of the external sphincter is pelvic relaxation training. We found that a large post-void residual might be a good parameter in the differential diagnosis of bladder neck dysfunction and dysfunctional voiding/poor relaxation of the external sphincter. We proposed a cutoff value of post-void residual = 200 mL to differentiate bladder neck dysfunction from the dysfunctional voiding/poor relaxation of the external sphincter (Fig. 2C). Thus, for women with urodynamic and clinical findings consistent with BOO, and with a post-void residual > 200 mL, especially for those women refractory to alpha blocker treatment, a videourodynamic study or at minimum a voiding cistourethrogram should be performed to exclude bladder neck dysfunction.

Many authors categorize non-neurologic functional BOO into two types (i.e., bladder neck dysfunction and dysfunctional voiding). and such dysfunctional voiding can be diagnosed by (1) intermittent and/or fluctuating flow rate due to involuntarily intermittent contractions of the periurethral striated muscle during voiding in a neurologically normal individuals and (2) urethral dilation to the level of the external sphincter with wide opening of bladder neck; and pelvic floor or striated external sphincter muscle should be responsible for the pathophysiology. We further classified the above diagnosis of dysfunctional voiding into two subtypes (i.e., dysfunctional voiding and poor relaxation of the external sphincter). Although the treatment for women with dysfunctional voiding and poor relaxation of the external sphincter may be similar, we found that the Pdet.Qmax was higher in dysfunctional voiding than in poor relaxation of the external sphincter (mean: 46 vs. 17 cmH2O, P < 0.0001) and had a high ROC area (0.93). In addition, the prevalence of detrusor overactivity was low in the poor relaxation of the external sphincter group (6%) compared to the other groups of functional BOO (46% and 60% for bladder neck dysfunction and dysfunctional voiding, respectively). Such a great difference may probably indicate that the chance of finding a diagnosis of poor relaxation of the external sphincter in a BOO woman without detrusor overactivity. Together with the typical videourodynamic findings (i.e., narrowing of the urethra at the middle part in dysfunctional voiding and at the distal part in poor relaxation of the external sphincter, Fig. 1C and D), these findings suggest that dysfunctional voiding and poor relaxation of the external sphincter are different disease entities with different pathogeneses. In brief, the voiding difficulty of dysfunctional voiding is functional BOO; and voiding difficulty of poor relaxation of the external sphincter is the guarding inhibition of the detrusor contraction during voiding attempt.

The bladder contractility index is represented by the following formula: bladder contractility index = Pdet. Qmax + 5 x Qmax. Using this formula, bladder contractility can be divided into strong (>150), normal (100–150), and weak (<100). The mean bladder contractility index was <100 in women with bladder dysfunction. The mean bladder contractility index was highest in women with detrusor overactivity or bladder oversensitivity, intermediate in women with detrusor hyperactivity and impaired contractility, and lowest in women with detrusor underactivity/acontractile detrusor (Table 3). Chancellor reported that the overactive bladder may progress to an underactive bladder. Early education, behavior modification and medical treatment may help to prevent this progression in women with overactive bladder.

In Table 1, we found that the incidence of diabetes mellitus was higher in the BOO group than in the bladder dysfunction group, and these may be associated with diabetes-related peripheral neuropathy of the bladder and impaired urethral relaxation during voiding. Reduced activity of the nitric oxide pathway may contribute to the impaired urethral relaxation in diabetes patients.

This study has limitations. The retrospective nature of this study may not represent the real prevalence of women with symptoms of voiding dysfunction in the general population. However, the large sample size study may make our data useful and more reliable. In addition, owing to the low ROC area of the Abrams-Griffiths number in predicting anatomic BOO, of the post-void residual in predicting bladder neck dysfunction and of the bladder contractility index in predicting bladder dysfunction, Abrams-Griffiths number, post-void residual and bladder contractility index may be not very helpful in determining cutoff values.

In conclusions, the videourodynamic findings of a large cohort of women with voiding dysfunction symptoms were presented, and can be used as initial guide for clinical management of female BOO.

**Methods**

Between Oct 1997 and Jan 2015, medical records of women with complaints of voiding dysfunction (e.g. hesitancy, difficult urination, slow stream, intermittency, postmicturition leakage or urinary retention) who underwent videourodynamic studies at the Department of Urology of a medical center were reviewed. The symptoms of these patients were classified into 4 groups at the time-point of videourodynamic studies, including (1) voiding symptoms (including hesitancy, dysuria, slow stream or feeling of incomplete emptying), (2) urgency and/or urgency urinary incontinence, (3) frequency/nocturia, and (4) urinary retention (episodic or chronic). All
patients had mild to severe voiding symptoms. However, only moderate and severe voiding symptoms were included in this retrospective analysis (Tables 1–3). The patients’ comorbidities, videourodynamic characteristics and urodynamic parameters were also recorded. Patients with a history of genitourinary tract cancer, overt neurogenic bladder dysfunction, high grade cystocele or prolapse, prior surgery for stress urinary incontinence, an established diagnosis of interstitial cystitis/painful bladder syndrome, chronic or active urinary tract infection were excluded. The diagnosis was made according to terminology from the International Continence Society.24, 30, 31

The institutional review board of the hospital approved this study. This study investigated the videourodynamic characteristics of female voiding dysfunction. No image that could lead to identification of a study participant will be published in the manuscript. The study was approved by the Institution Review Board of the hospital (IRB: 100-06). Informed consent was waived due to its’ retrospective analysis. The corresponding author confirmed that all methods were performed in accordance with relevant guidelines and regulations.

Videourodynamic studies were performed using multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) and a C-arm fluoroscope (Toshiba, Tokyo, Japan) prior to any treatment. The procedure was performed in the sitting position with a 6 Fr dual-channel urethral catheter for recording the intravesical pressure, and the warm normal saline containing 20% urograffin was used for infusion. The intra-abdominal pressure was recorded using a 6 Fr rectal balloon catheter. The videourodynamic study was performed at a filling rate of 20–30 mL/min. The C-arm fluoroscope was positioned at 45 degrees from the buttocks so that the urethra could be lengthened and so that the bladder neck, urethral sphincter, and distal urethra could be clearly identified. Urethral sphincter electromyography was recorded using surface patch electromyography electrodes placed at the perianal area. The videourodynamic study was repeated at least once to demonstrate the reproducibility of the findings during the first examination. All descriptions and terminology for the urodynamic parameters were in accordance with the recommendations of the International Continence Society.24, 30. Bladder capacity was derived from the sum of the voided volume and the post-void residual. Voiding efficiency was defined as the voided volume divided by bladder capacity.

A Pdet.Qmax of more than 35 cmH₂O was considered a high Pdet.Qmax, while 10–35 cmH₂O was considered a normal Pdet.Qmax, and 10 cmH₂O or less was considered a low Pdet.Qmax.31 Patients with a stable bladder, normal bladder sensation, a cystometric bladder capacity > 350 mL, a normal Pdet.Qmax or a low Pdet.Qmax but with a Qmax > 15 mL/s, and a post-void residual less than 10% of cystometric bladder capacity were considered urodynamically normal.31 An acontractile detrusor is one that cannot be demonstrated to contract during urodynamic studies.30 When patients had a Pdet.Qmax < 10 cmH₂O and needed to void via abdominal straining or were unable to void, detrusor underactivity was diagnosed.36 Detrusor hyperactivity and impaired contractility was defined as the presence of involuntary detrusor contraction during the filling phase and underactive detrusor function during the voiding phase, usually with a voiding efficiency of < 50%.33, 34

Detrusor overactivity was defined as evidence of spontaneous detrusor contractions occurring during bladder filling or an uninhibited detrusor contraction occurring at cystometric capacity that usually resulting in voiding.40, 41 If patients had a strong desire to void at a cystometric bladder capacity of less than 350 mL and without the occurrence of detrusor overactivity, they were considered to have bladder oversensitivity.24, 30 However, some women

### Table 3. Comparisons of videourodynamic diagnoses with bladder dysfunction (n = 1,048) DHIC = detrusor hyperactivity with impaired contractility. Data expression and other abbreviations are the same as in Table 1.

| Variables | Acontractile detrusor (n = 106) | Detrusor underactivity (n = 337) | DHIC (n = 231) | Detrusor overactivity (n = 49) | Bladder oversensitivity (n = 325) | P* |
|-----------|-------------------------------|-------------------------------|----------------|-------------------------------|-------------------------------|-----|
| Age (years) | 62.5 ± 13.8 | 67.8 ± 14.5 | 75.6 ± 9.5 | 67.5 ± 15.3 | 54.1 ± 16.0 | 0.0001 |
| Detrusor overactivity | 2 (2) | 11 (3) | 231 (100) | 49 (100) | 13 (4) | < 0.001 |
| First sensation of filling (mL) | 207 ± 118 | 196 ± 106 | 139 ± 72 | 131 ± 70 | 118 ± 53 | 0.0001 |
| Full sensation (mL) | 300 ± 132 | 289 ± 129 | 196 ± 101 | 186 ± 92 | 194 ± 72 | 0.0001 |
| Bladder compliance (mL/cmH₂O) | 51 ± 87 | 70 ± 93 | 58 ± 69 | 51 ± 55 | 66 ± 69 | 0.0001 |
| Voided volume (mL) | 81 ± 109 | 116 ± 123 | 104 ± 82 | 230 ± 124 | 235 ± 86 | 0.0001 |
| Post-void residual (mL) | 331 ± 199 | 271 ± 198 | 195 ± 143 | 28 ± 41 | 34 ± 75 | 0.0001 |
| Bladder capacity (mL) | 412 ± 162 | 387 ± 169 | 299 ± 156 | 258 ± 125 | 269 ± 90 | 0.0001 |
| Pdet.Qmax (cmH₂O) | 4.7 ± 8.1 | 8.5 ± 9.8 | 18.0 ± 9.4 | 20.3 ± 10.1 | 18.8 ± 9.6 | 0.0001 |
| Qmax (mL/s) | 3.6 ± 5.4 | 4.9 ± 5.3 | 6.3 ± 4.4 | 13.0 ± 8.3 | 12.4 ± 5.9 | 0.0001 |
| Abrams-Griffith number | −2.5 ± 12.7 | −1.3 ± 12.9 | 5.4 ± 13.7 | −5.7 ± 21.1 | −6.0 ± 13.8 | 0.0001 |
| Voided volume/bladder capacity (%) | 0.23 ± 0.30 | 0.34 ± 0.34 | 0.36 ± 0.22 | 0.88 ± 0.14 | 0.88 ± 0.20 | 0.0001 |
| Bladder contractility index | 22.7 ± 29.1 | 33.2 ± 30.2 | 49.6 ± 22.9 | 85.2 ± 40.9 | 80.7 ± 32.2 | 0.0001 |
| Moderate/severe voiding symptoms | 90 (85) | 273 (81) | 143 (62) | 17 (35) | 101 (31) | < 0.001 |
| Urgency/UUI | 29 (27) | 87 (26) | 194 (84) | 43 (88) | 197 (61) | < 0.001 |
| Frequency/nocturia | 67 (63) | 274 (81) | 174 (75) | 39 (80) | 302 (93) | < 0.001 |
| Urinary retention | 40 (38) | 117 (35) | 60 (26) | 3 (6) | 13 (4) | < 0.001 |
diagnosed as detrusor underactivity or bladder oversensitivity had concomitant urgency and low amplitude detrusor overactivity (< 5 cm H2O) during bladder filling, we did not classify these women to detrusor hyperactivity or impaired contractility or detrusor overactivity. Bladder compliance was measured as the incrementally increased cystometric volume at full bladder sensation divided by the increased detrusor pressure.

Women with voiding symptoms were classified as obstructed if there was radiographic evidence of obstruction between the bladder neck and distal urethra in the presence of a sustained detrusor contraction, which was usually associated with reduced or delayed urinary flow rate. The final diagnosis of bladder neck dysfunction, dysfunctional voiding or poor relaxation of the external sphincter was made based on the main videourodynamic findings. Voiding cystourethrogram showed narrowing of the urethra at the proximal part in bladder neck dysfunction (Fig. 1B), the middle part in dysfunctional voiding (Fig. 1C), and at the distal part in poor relaxation of the external sphincter (Fig. 1D). In bladder neck dysfunction, besides a high voiding pressure and a low flow rate, a lack of significantly increased electromyography activity and a non-funneling appearance of the bladder neck on fluoroscopy were also noted on videourodynamic findings. In dysfunctional voiding, intermittent electromyography activity was found during the voiding phase, causing an increase in voiding pressure. In poor relaxation of the external sphincter, the electromyography activity did not decrease during attempts at voiding, resulting in a low voiding pressure or straining to void. Cystoscopy was used in conjunction with the videourodynamic findings for differential diagnosis of the etiology of BOO.

STATA software (Version 11.0; Stata Corp, College Station, TX, USA) was used for statistical analyses. The Kruskal-Wallis test and Wilcoxon rank-sum test were used as appropriate. A P value of less than 0.05 was considered statistically significant. The ROC curve analysis was performed to identify optimal cutoff values. The optimal cutoff value was determined by the point on the ROC curve that was closest to the upper left-hand corner.

References
1. Kuo, H. C. Clinical symptoms are not reliable in the diagnosis of lower urinary tract dysfunction in women. J Formos Med Assoc 111, 386–391 (2012).
2. Nitti, V. W. Pressure flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. Rev Urol 7(Suppl 6), S14–S21 (2005).
3. Lin, C. D., Kuo, H. C. & Yang, S. S. Diagnosis and management of bladder outlet obstruction in women. Low Urin Tract Symptoms 8, 30–37 (2016).
4. Kuo, H. C. Videourodynamic characteristics and lower urinary tract symptoms of female bladder outlet obstruction. Urology 66, 1005–1009 (2005).
5. Nitti, V. W., Tu, L. M. & Gitlin, J. Diagnosing bladder outlet obstruction in women. J Urol 161, 1355–1359 (1999).
6. Akikawa, T. V., Fleischman, N. & Nitti, V. W. Comparison of diagnostic criteria for female bladder outlet obstruction. J Urol 176, 2093–2097 (2006).
7. Brucker, B. M. et al. Comparison of urodynamic findings in women with anatomical versus functional bladder outlet obstruction. Female Pelvic Med Reconstr Surg 19, 46–50 (2013).
8. Grouzit, A., Blaivas, J. G. & Chaikin, D. C. Bladder outlet obstruction in women: definition and characteristics. Neurourol Urodyn 19, 213–220 (2000).
9. Defreitas, G. A., Zimmern, P. E., Lemack, G. E. & Shariat, S. F. Refining diagnosis of anatomic female bladder outlet obstruction: Comparison of pressure-flow study parameters in clinically obstructed women with those of normal controls. Urology 64, 675–679 (2004).
10. Abrams, P. Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function. BJU Int 84, 14–15 (1999).
11. Chassagne, S. et al. Proposed cutoff values to define bladder outlet obstruction in women. Urology 51, 408–411 (1998).
12. Massey, J. A. & Abrams, P. H. Obstructed voiding in the female. Br J Urol 61, 36–39 (1988).
13. Lemack, G. E. & Zimmern, P. E. Pressure flow analysis may aid in identifying women with outflow obstruction. J Urol 163, 1823–1828 (2000).
14. Defreitas, G. A., Zimmern, P. E., Lemack, G. E. & Shariat, S. F. Refining diagnosis of anatomic female bladder outlet obstruction: Comparison of pressure-flow study parameters in clinically obstructed women with those of normal controls. Urology 64, 675–679 (2004).
15. Kuo, H. C. Urodynamic parameters for the diagnosis of bladder outlet obstruction in women. J Urol 172, 46–51 (2004).
16. Chen, C. H., Hsiao, S. M., Chang, T. C., Wu, W. Y. & Lin, H. H. Clinical and urodynamic effects of bacleoren in women with functional bladder outlet obstruction: Preliminary report. J Obstet Gynaecol Res 42, 560–565 (2016).
17. Blaivas, J. G. & Grouzit, A. Bladder outlet obstruction nomogram for women with lower urinary tract symptomatology. Neurourol Urodyn 19, 553–564 (2000).
18. Gravina, G. L. et al. Bladder outlet obstruction index and maximal flow rate during urodynamic study as powerful predictors for the detection of urodynamic obstruction in women. Neurourol Urodyn 26, 247–253 (2007).
19. Grifiths, D. et al. Standardisation of terminology in lower urinary tract function: pressure flow studies of voiding, urethral resistance, and urethral obstruction. International Continence Society Subcommittee on Standardization of Terminology of Pressure-Flow Studies. Neurourol Urodyn 16, 1–18 (1997).
20. Abrams, P. Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function. BJU Int 84, 14–15 (1999).
21. Chassagne, S. et al. Proposed cutoff values to define bladder outlet obstruction in women. Urology 51, 408–411 (1998).
22. Massey, J. A. & Abrams, P. H. Obstructed voiding in the female. Br J Urol 61, 36–39 (1988).
23. Lemack, G. E. & Zimmern, P. E. Pressure flow analysis may aid in identifying women with outflow obstruction. J Urol 163, 1823–1828 (2000).
24. Defreitas, G. A., Zimmern, P. E., Lemack, G. E. & Shariat, S. F. Refining diagnosis of anatomic female bladder outlet obstruction: Comparison of pressure-flow study parameters in clinically obstructed women with those of normal controls. Urology 64, 675–679 (2004).
25. Kuo, H. C. Urodynamic parameters for the diagnosis of bladder outlet obstruction in women. J Urol 172, 46–51 (2004).
26. Chen, C. H., Hsiao, S. M., Chang, T. C., Wu, W. Y. & Lin, H. H. Clinical and urodynamic effects of bacleoren in women with functional bladder outlet obstruction: Preliminary report. J Obstet Gynaecol Res 42, 560–565 (2016).
27. Blaivas, J. G. & Grouzit, A. Bladder outlet obstruction nomogram for women with lower urinary tract symptomatology. Neurourol Urodyn 19, 553–564 (2000).
28. Gravina, G. L. et al. Bladder outlet obstruction index and maximal flow rate during urodynamic study as powerful predictors for the detection of urodynamic obstruction in women. Neurourol Urodyn 26, 247–253 (2007).
29. Grifiths, D. et al. Standardisation of terminology in lower urinary tract function: pressure flow studies of voiding, urethral resistance, and urethral obstruction. Neurourol Urodyn 16, 1–18 (1997).
30. Blaivas, J. G., Flisser, A. & Tash, J. A. Treatment of primary bladder neck obstruction in women with transurethral resection of the bladder neck. J Urol 171, 1172–1175 (2004).
31. Peng, C. H. & Kuo, H. C. Transurethral incision of bladder neck in treatment of bladder neck obstruction in women. Urology 65, 275–278 (2005).
32. Minardi, D. et al. The role of uroflowmetry biofeedback and biofeedback training of the pelvic floor muscles in the treatment of recurrent urinary tract infections in women with dysfunctional voiding: a randomized controlled prospective study. Urology 72, 1299–1304 (2010).
33. Hickling, D., Aponte, M. & Nitti, V. Evaluation and management of outlet obstruction in women without anatomical abnormalities on physical exam or cystoscopy. Curr Urol Rep 13, 356–362 (2012).
34. Abrams, P. et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21, 167–178 (2002).
35. Grouzit, A. & Blaivas, J. G. Non-neurogenic female voiding dysfunction. Curr Opin Urol 12, 311–316 (2002).
36. Deindl, F. M., Vodusek, D. B., Bischoff, C., Hofmann, R. & Hartung, R. Dysfunctional voiding in women: which muscles are responsible? Br J Urol 82, 814–819 (1998).
37. Chancellor, M. B. The overactive bladder progression to underactive bladder hypothesis. Int Urol Nephrol 46(Suppl 1), S23–S27 (2014).
28. Kirschner-Hermanns, R. et al. Does diabetes mellitus-induced bladder remodeling affect lower urinary tract function? ICI-RS 2011. Neurourol Urodyn 31, 359–364 (2012).
29. Mumtaz, F. H., Khan, M. A., Thompson, C. S., Morgan, R. J. & Mikhailidis, D. P. Nitric oxide in the lower urinary tract: physiological and pathological implications. BJU Int 85, 567–578 (2000).
30. Haylen, B. T. et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21, 5–26 (2010).
31. Chen, Y. C. & Kuo, H. C. Clinical and video urodynamic characteristics of adult women with dysfunctional voiding. J Formos Med Assoc 113, 161–165 (2014).
32. Kuo, H. C. Clinical symptoms are not reliable in the diagnosis of lower urinary tract dysfunction in women. J Formos Med Assoc 111, 386–91 (2012).
33. Resnick, N. M. & Yalla, S. V. Detrusor hyperactivity with impaired contractile function. An unrecognized but common cause of incontinence in elderly patients. JAMA 257, 3076–3081 (1987).
34. Wang, C. C., Lee, C. L. & Kuo, H. C. Efficacy and safety of intravesical onabotulinumtoxinA injection in patients with detrusor hyperactivity and impaired contractility. Toxins (Basel) 8, 82 (2016).
35. Kuo., H. C. Videourodynamic study for diagnosis of bladder outlet obstruction in women. J Formos Med Assoc 99, 386–392 (2000).

Author Contributions
H.C.K. designed the study. S.M.H. analyzed the data. S.M.H. and H.H.L. wrote the paper.

Additional Information
Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017